SEPN Septerna, Inc.
Nasdaq · SEC CIK 1984086 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $61.26M 16 sales by 5 insiders
- Filings on record
- 60 since 2024-10-28, latest 2026-09-10 17:08
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | — | $63.45M |
| Shaikhly Samira | CHRO | — | $2.80M |
| Bhatt Elizabeth | Pres, COO | — | $1.45M |
| Long Daniel D. | SVP, Drug Discovery | — | $951.3K |
| Third Rock Ventures V, L.P. | 10% | — | -$7.40M |
Transactions 44
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-03 19:01 | 2026-09-01 | SEPN | Long Daniel D. | SVP, Drug Discovery | M - OptEx | $2.76 | +3,333 | 99.7K | +3% | +$9,199 |
| DT | 2026-09-03 19:01 | 2026-09-01 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $37.83 | -3,333 | 96.4K | -3% | -$126.1K |
| MT | 2026-08-14 17:44 | 2026-08-12 | SEPN | Third Rock Ventures V, L.P. | 10% | S - Sale | $50.27 | +147.2K | 6.07M | +2% | +$7.40M |
| MI | 2026-08-14 17:11 | 2026-08-12 | SEPN | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | S - Sale | $42.50 | -1.49M | 725.4K | -67% | -$63.45M |
| DMT | 2026-08-13 19:00 | 2026-08-11 | SEPN | Bhatt Elizabeth | Pres, COO | M - OptEx | $5.79 | +25.0K | 199.2K | +14% | +$144.7K |
| DT | 2026-08-13 19:00 | 2026-08-11 | SEPN | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $44.00 | -25.0K | 174.2K | -13% | -$1.10M |
| DMT | 2026-08-05 19:00 | 2026-08-03 | SEPN | Long Daniel D. | SVP, Drug Discovery | M - OptEx | $2.76 | +3,334 | 99.7K | +3% | +$9,202 |
| DMT | 2026-08-05 19:00 | 2026-08-03 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $34.47 | -3,334 | 96.4K | -3% | -$114.9K |
| DT | 2026-07-17 19:00 | 2026-07-15 | SEPN | Bhatt Elizabeth | Pres, COO | M - OptEx | $6.81 | +4,000 | 178.2K | +2% | +$27.2K |
| DT | 2026-07-17 19:00 | 2026-07-15 | SEPN | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $33.99 | -4,000 | 174.2K | -2% | -$136.0K |
| DT | 2026-07-02 19:00 | 2026-07-01 | SEPN | Long Daniel D. | SVP, Drug Discovery | M - OptEx | $2.76 | +3,333 | 99.7K | +3% | +$9,199 |
| DMT | 2026-07-02 19:00 | 2026-07-01 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $34.36 | -3,333 | 96.4K | -3% | -$114.5K |
| DT | 2026-06-30 19:01 | 2026-06-29 | SEPN | Shaikhly Samira | CHRO | M - OptEx | $6.81 | +2,178 | 2,971 | +275% | +$14.8K |
| DT | 2026-06-30 19:01 | 2026-06-29 | SEPN | Shaikhly Samira | CHRO | S - Sale+OE | $35.18 | -2,178 | 793 | -73% | -$76.6K |
| DMT | 2026-06-24 19:24 | 2026-06-22 | SEPN | Long Daniel D. | SVP, Drug Discovery | M - OptEx | $5.42 | +15.0K | 111.4K | +16% | +$81.4K |
| DMT | 2026-06-24 19:24 | 2026-06-22 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $35.51 | -15.0K | 96.4K | -13% | -$532.6K |
| DT | 2026-06-16 20:31 | 2026-06-12 | SEPN | Shaikhly Samira | CHRO | M - OptEx | $11.70 | +6,250 | 7,043 | +788% | +$73.1K |
| DT | 2026-06-16 20:31 | 2026-06-12 | SEPN | Shaikhly Samira | CHRO | S - Sale+OE | $35.08 | -6,250 | 793 | -89% | -$219.2K |
| DMT | 2026-06-03 19:11 | 2026-06-01 | SEPN | Shaikhly Samira | CHRO | M - OptEx | $1.87 | +5,935 | 6,728 | +748% | +$11.1K |
| DMT | 2026-06-03 19:11 | 2026-06-01 | SEPN | Shaikhly Samira | CHRO | S - Sale+OE | $28.93 | -5,935 | 793 | -88% | -$171.7K |
| DT | 2026-05-28 19:02 | 2026-05-26 | SEPN | Shaikhly Samira | CHRO | M - OptEx | $6.81 | +11.8K | 12.6K | +1,488% | +$80.3K |
| DT | 2026-05-28 19:02 | 2026-05-26 | SEPN | Shaikhly Samira | CHRO | S - Sale+OE | $30.06 | -11.8K | 793 | -94% | -$354.7K |
| DT | 2026-04-17 19:00 | 2026-04-15 | SEPN | Bhatt Elizabeth | Pres, COO | M - OptEx | $6.81 | +4,000 | 178.2K | +2% | +$27.2K |
| DMT | 2026-04-17 19:00 | 2026-04-15 | SEPN | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $24.34 | -4,000 | 174.2K | -2% | -$97.3K |
| DMT | 2026-03-04 | 2026-03-02 | SEPN | Shaikhly Samira | CHRO | S - Sale+OE | $28.10 | -70.5K | 67.2K | -51% | -$1.98M |
| DMT | 2026-03-04 | 2026-03-02 | SEPN | Shaikhly Samira | CHRO | M - OptEx | $1.84 | +70.5K | 54.5K | New | +$129.5K |
| DMT | 2026-02-20 | 2026-02-18 | SEPN | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $28.96 | -4,000 | 176.0K | -2% | -$115.9K |
| DT | 2026-02-20 | 2026-02-18 | SEPN | Bhatt Elizabeth | Pres, COO | M - OptEx | $6.81 | +4,000 | 178.2K | +2% | +$27.2K |
| 2025-11-13 | 2025-11-10 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale | $18.06 | -3,501 | 92.9K | -4% | -$63.2K | |
| DM | 2025-08-19 | 2025-08-18 | SEPN | Klein Uwe | SVP, Biological Sciences | M - OptEx | $4.10 | +23.0K | 15.4K | New | +$94.4K |
| DM | 2025-04-04 | 2025-04-02+ | SEPN | Finer Jeffrey | CEO, Pres, Dir | M - OptEx | $2.76 | +55.0K | 821.9K | +7% | +$151.8K |
| 2025-03-10 | 2025-03-07 | SEPN | Ezekowitz Alan | Dir | P - Purchase | $6.93 | +13.3K | 117.4K | +13% | +$92.3K | |
| M | 2025-03-06 | 2025-03-04+ | SEPN | Ezekowitz Alan | Dir | P - Purchase | $5.95 | +86.7K | 104.1K | +498% | +$515.9K |
| MI | 2025-02-27 | 2025-02-25+ | SEPN | Labrucherie Gil M | CFO | P - Purchase | $5.69 | +10.0K | 40.0K | +33% | +$56.9K |
| M | 2025-02-27 | 2025-02-25+ | SEPN | Finer Jeffrey | CEO, Pres, Dir | P - Purchase | $5.71 | +17.0K | 768.9K | +2% | +$97.0K |
| 2025-02-26 | 2025-02-24 | SEPN | Third Rock Ventures GP V, LP | 10% | P - Purchase | $6.00 | +18.9K | 4.21M | +0.4% | +$113.2K | |
| M | 2025-02-24 | 2025-02-20+ | SEPN | Third Rock Ventures GP V, LP | 10% | P - Purchase | $5.93 | +1.04M | 3.77M | +38% | +$6.17M |
| MI | 2025-02-21 | 2025-02-19+ | SEPN | Labrucherie Gil M | CFO | P - Purchase | $5.75 | +30.0K | 10.5K | New | +$172.4K |
| DMI | 2024-10-30 | 2024-10-28 | SEPN | Shah Rajeev M. | Dir, 10% | C - Cnv Deriv | — | +2.83M | 1.13M | New | — |
| DMI | 2024-10-30 | 2024-10-28 | SEPN | Shah Rajeev M. | Dir, 10% | P - Purchase | $18.00 | +4.17M | 1.47M | New | +$75.06M |
| D | 2024-10-28 | 2024-10-28 | SEPN | TRV GP V, LLC | 10% | C - Cnv Deriv | $0.00 | +4.79M | 5.85M | +454% | $0 |
| D | 2024-10-28 | 2024-10-28 | SEPN | TRV GP V, LLC | 10% | P - Purchase | $18.00 | +370.5K | 6.22M | +6% | +$6.67M |
| DI | 2024-10-28 | 2024-10-28 | SEPN | TRV GP V, LLC | 10% | C - Cnv Deriv | $0.00 | +2.87M | 2.87M | New | $0 |
| DI | 2024-10-28 | 2024-10-28 | SEPN | TRV GP V, LLC | 10% | P - Purchase | $18.00 | +279.5K | 3.15M | +10% | +$5.03M |
Purchase Sale Sale after option exercise All abbreviations